Mozart Therapeutics Adds $25M to Earlier Series A Round


Seattle-based biotech Mozart Therapeutics, which generates treatments for inflammatory and autoimmune diseases, has raised $25 million in funding. This investment follows an initial $55 million secured in a previous Series A round. The company will use this funding to support clinical trials, which it hopes to launch in 2024.

Mozart Therapeutics was created in 2020 and is headed by CEO Katie Fanning. While several companies including Eli Lilly & Company and Sofinnova Partners had previously invested in the biotech firm, this round of funding introduced Pfizer Ventures, AbbVie Ventures and other major companies to Mozart Therapeutics’ shareholders. 

“We have made significant progress toward our mission of developing disease-modifying therapeutics that restore immune balance, and this additional capital will help support the advancement of our lead candidate,” Fanning said.